Bubba and badger breakdown high frequency trading in depth. We give our opinion on the book the flash boys.…
Fracking has been called a “revolution” by the oil and gas industry. But how long can the boom last?
Oil and gas has been a safe place to invest your money for the last century or so. Sure, there were…
U.S. stock futures barely budged in pre-market trading Wednesday as positive earnings news from U.S. companies was offset by a disappointing economic report from China .
KEEPING SCORE: Standard & Poor’s 500 index futures eased two points, or 0.1 percent,…
Unisys Corporation reported first quarter 2014 net loss of $53.5 million or $1.15 per share compared with a net loss of $33.9 million or 77 cents per share in the year-earlier quarter.
Cubist Pharma missed both on earnings and revenues.
Prologis reported core FFO per share of 43 cents, which was a penny above the Zacks Consensus Estimate and 3 cents ahead of the year-ago quarter figure.
Juniper Networks Inc. (JNPR) reported adjusted earnings per share of 16 cents in the first quarter of 2014, which lagged the Zacks Consensus Estimate of 19 cents.
Stocks that cater to growing sectors such as mobile, social networking and Big Data analytics are attractive
Skechers (SKX) kick-started 2014 as its top and bottom lines for the first quarter surpassed the Zacks Consensus Estimate and recorded year-over-year growth as well.
Liberty Property’s first-quarter 2014 FFO of 58 cents per share fell a penny short of the Zacks Consensus Estimate and came 7 cents below the prior-year quarter figure.
Shares of TCF Financial Corporation rallied more than 2% following the release of its first-quarter 2014 results that reflected 50% year-over-year rise in earnings per share
FMC Technologies, Inc. reported another stellar quarter amid improvements in all its business segments, primarily its Subsea business.
iRobot beats the Zacks Consensus Estimate for earnings and revenues in the first quarter of 2014.
Thanks to some big banks reporting as of late, these financial ETFs look to be in focus.
Anacor Pharmaceuticals, Inc. focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company’s lead product candidates include tavaborole, an antifungal product candidate that is in Phase III clinical development for the treatment of…